Stock

Cytokinetics, Incorporated CYTK

$81.02-1.17%

All stocks Create account to unlock

Overview

CYTK market data

Price History

CYTK price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for CYTK. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

10 captured

Cytokinetics to Announce Second Quarter Results on August 6, 2026 · Jul 23, 2026, 8:15 PM

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% · Jul 14, 2026, 10:15 PM

RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $117 · Jul 7, 2026, 4:20 PM

Cytokinetics To Present Late Breaking Science At ESC Congress, Including Phase 3 ACACIA‑HCM Results · Jul 7, 2026, 11:45 AM

UBS Upgrades Cytokinetics to Buy, Raises Price Target to $115 · Jun 29, 2026, 4:30 PM

Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $118 · Jun 24, 2026, 1:10 PM

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Jun 17, 2026, 8:15 PM

Cytokinetics Opens Applications for Corporate Giving Program, to Fund Health, Science Education and Community Nonprofits · Jun 8, 2026, 11:45 AM

Cytokinetics Announces First Commercial European Launch Of MYQORZO In Germany For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult Patients · Jun 1, 2026, 11:38 AM

Cytokinetics to Participate in June Investor Conferences · May 27, 2026, 8:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock